Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metronomic Temozolomide and Irinotecan in Recurrent Glioblastoma
NCT01308632Phase 3Unknown
- Sponsor
- Grupo Español de Investigación en Neurooncología
- Start
- Nov 2007
- Primary completion
- Jun 2012
- Modality
- Small Molecules
01
Overview
Phase 3, open-label trial of irinotecan in glioblastoma (GBM), sponsored by Grupo Español de Investigación en Neurooncología. Primary endpoint: Maximum Tolerated Dose at 28 days. Status: unknown.
02
Drugs
irinotecan
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT01308632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01308632.